Pest control using natural pest control agent blends 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2009117623 A2 2009-09-24 [WO2009117623]WO2009117623 A3 2010-01-07 [WO2009117623] / 2009-09-242010-01-07
申请号/申请日
2009WO-US37735 / 2009-03-19
发明人
ENAN ESSAM;
申请人
TYRATECH;
主分类号
IPC分类号
A01N-025/00A61K-036/28
摘要
(WO2009117623) Embodiments of the invention relate to a composition for controlling a target pest, wherein the composition includes at least two active ingredients selected from the group consisting of thymyl acetate, linalyl acetate, amyl butyrate, anise star oil, black seed oil, p-cymene, geraniol, isopropyl myristate, d-limonene, linalool, lilac flower oil, methyl salicylate, alpha-pinene, piperonal, piperonyl alcohol, tetrahydrolinalool, thyme oil white, thyme oil red, thymol, vanillin, and wintergreen oil, wherein the composition causes synergistic control of the target pest.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2008US-61043084 2008-04-07 2008US-61070137 2008-03-19 2008US-61102784 2008-10-03
主权利要求
(WO2009117623) CLAIMS What is claimed is: 1. A composition for controlling a target pest comprising at least two active ingredients selected from the group consisting of thymyl acetate, linalyl acetate, amyl butyrate, anise star oil, black seed oil, p-cymene, geraniol, isopropyl myristate, d- limonene, linalool, lilac flower oil, methyl salicylate, alpha-pinene, piperonal, piperonyl alcohol, tetrahydrolinalool, thyme oil white, thyme oil red, thymol, vanillin, and wintergreen oil, wherein the composition causes synergistic control of the target pest. 2. The composition of Claim 1, wherein the target pest is an endoparasite, and wherein the composition comprises at least two active ingredients selected from the group consisting of alpha-pinene, thymol, para-cymene, linalool, thymyl acetate, and linalyl acetate. 3. The composition of Claim 2, comprising at least three active ingredients selected from said group. 4. The composition of Claim 2, comprising alpha-pinene, thymol, para- cymene, and linalool. 5. The composition of Claim 2, comprising alpha-pinene, para-cymene, thymyl acetate, and linalyl acetate. 6. The composition of Claim 4 or 5, wherein alpha-pinene is present in an amount within a range of 1-10%, thymol or thymol acetate is present in an amount within a range of 20-75%, para-cymene is present within a range of 2%-50%, and linalool or linalyl acetate is present within a range of 3%-40%. 7. The composition of Claim ,6 wherein wherein alpha-pinene is present in an amount within a range of 4%-8%, thymol or thymol acetate is present in an amount within a range of 30-65%, para-cymene is present within a range of 4%-40%, and linalool or linalyl acetate is present within a range of 6%-30%. 8. The composition of Claim 2, wherein said active ingredients are encapsulated using an encapsulating agent. 9. The composition of Claim 2, wherein the endoparasite is a flatworm. 10. The composition of Claim 9, wherein the flatworm is Hymenolepsis nana. 11. The composition of Claim 2, wherein the endoparasite is a roundworm. 12. The composition of Claim 11, wherein the roundworm is Ascaris suum or Toxocara canis. 13. The composition of Claim 1, wherein the target pest is an ectoparasite, and wherein the composition comprises at least two active ingredients selected from the group consisting of amyl butyrate, anise star oil, black seed oil, p-cymene, geraniol, isopropyl myristate, d-limonene, linalool, lilac flower oil, methyl salicylate, alpha-pinene, piperonal, piperonyl alcohol, tetrahydrolinalool, thyme oil white, thyme oil red, thymol, vanillin, and wintergreen oil. 14. The composition of Claim 13, wherein the at least two active ingredients are selected from the group consisting of geraniol, d-limonene, linalool, piperonal, tetrahydrolinalool, and vanillin. 15. The composition of Claim 14, wherein geraniol is present within an range of 3%-30%, d-limonene is present within an amount of 7%-30%, linalool is present within a range of 4%-20%, piperonal is present within a range of 2%-25%, tetrahydrolinalool is present within a range of 6%-22%, and vanillin is present within a range of 0.3%- 1.5%. 16. The composition of Claim 13, wherein the at least two active ingredients are selected from the group consisting of amyl butyrate, anise star oil, and thyme oil white. 17. The composition of Claim 16, wherein amyl butyrate is present within a range of 15%-30%, anise star oil is present within a range of 40%-65%, and thyme oil white is present within a range of 15%-30%. 18. The composition of Claim 13, wherein the at least two active ingredients are thyme oil white and wintergreen oil. 19. The composition of Claim 18, wherein thyme oil white is present within a range of 10-30%, and wintergreen oil is present within a range of 25%-55%. 20. The composition of Claim 13, wherein the at least two active ingredients are selected from the group consisting of d-limonene, lilac flower oil, and thyme oil white. 21. The composition of Claim 20, wherein d-limonene is present within a range of 15%-35%, lilac flower oil is present within a range of 30%-55%, and thyme oil white is present within a range of 20%-40%. 22. The composition of Claim 13, wherein the at least two active ingredients are selected from the group consisting of alpha-pinene, thymol, para-cymene, and linalool. 23. The composition of Claim 22, wherein alpha-pinene is present in an amount within a range of 1-10%, thymol is present in an amount within a range of 25- 45%, para-cymene is present within a range of 20%-35%, and linalool is present within a range of 2%- 15%. 24. The composition of Claim 13, wherein the at least two active ingredients are selected from the group consisting of d-limonene, linalool, piperonal, piperonyl alcohol, tetrahydrolinalool, and vanillin. 25. The composition of Claim 24, wherein d-limonene is present within a range of 5%-15%, linalool is present within a range of 10%-25%, piperonal is present within a range of 15%-30%, piperonyl alcohol is present within a range of 5%-15%, tetrahydrolinalool is present within a range of 10%-30%, and vanillin is present within a range of 0.5%-5%. 26. The composition of any one of Claims 13-25, wherein the ectoparasite is one selected from the group of: a flea, a tick, a mosquito, a thrip, and a fly. 27. The composition of Claim 26, wherein the ectoparasite is selected from the group consisting of Ctenocephalides felis, Dermacentor andersoni, Rhipicephalus sanguineus, Aedes aegypti, and Stomoxys calcitrans. 28. An antiparasitic formulation, comprising the composition of any one of Claims 1-28, wherein the composition is present within a range of l%-30%, with the balance of the formulation comprising a solvent or surfactant. 29. A method of treating a parasitic infestation in a subject, comprising administering an effective amount of the composition of any one of Claims 1-27 or the antiparasitic formulation of Claim 28 to the subject. 30. Use of the composition of any of Claims 1-27 for the manufacture of a medicament for treating or preventing parasitic infection. 31. A pharmaceutical composition comprising a pharmaceutically adequate carrier or diluent and a sufficient amount of the the composition of any of Claims 1-27. 32. A method of making an improved agent for control of a target pest, comprising: providing a complex agent comprising a plurality of fractions; isolating at least a first fraction of the agent; screening the first fraction using a screening system comprising at least one invertebrate receptor to obtain a first screening result; comparing the first screening result with a second screening result, wherein the second screening result comprises an outcome of a screening of the complex agent against the at least one invertebrate receptor, and wherein the first and second screening results are indicative of a potential activity against the target pest; and changing a characteristic of the complex agent, thereby making the improved agent, wherein the changing is based upon information obtained from at least one of the screening step and the comparing step. 33. The method of Claim 32, wherein the first screening result comprises a value that is higher than that of the second screening result, and wherein the changing comprises increasing a relative amount of the first fraction. 34. The method of Claim 32, wherein the first screening result comprises a value that is lower than that of the second screening result, and wherein the changing comprises decreasing a relative amount of the first fraction. 35. The method of Claim 32, wherein the first fraction comprises a single active ingredient. 36. The method of Claim 32, wherein the first fraction comprises a plurality of ingredients. 37. The method of Claim 32, further comprising isolating a second fraction from said complex agent, and wherein the changing of a characteristic of the complex agent comprises combining said first and second fractions. 38. The method of Claim 32, further comprising the steps of: isolating at least a third fraction from said first fraction; screening the third fraction in a second screening step using said screening system to obtain a third screening result; comparing the third screening result with a fourth screening result in a second comparing step, wherein the fourth screening result comprises an outcome of a screening of the improved agent against at least one invertebrate receptor, and wherein the third and fourth screening results are indicative of a potential activity against the target pest; and changing a characteristic of the improved agent to make a further improved agent, wherein the changing is based upon information obtained from at least one of the second screening step and the second comparing step.
法律状态
(WO2009117623) LEGAL DETAILS FOR WO2009117623  Actual or expected expiration date=2011-10-07    Legal state=DEAD    Status=LAPSED     Event publication date=2009-03-19  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2009037735  Application date=2009-03-19  Standardized application number=2009WO-US37735     Event publication date=2009-09-24  Event code=WO/A2  Event type=Examination events  International application published with declaration under Article 17 (2) (a)  Publication country=WO  Publication number=WO2009117623  Publication stage Code=A2  Publication date=2009-09-24  Standardized publication number=WO2009117623     Event publication date=2010-01-07  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO2009117623  Publication stage Code=A3  Publication date=2010-01-07  Standardized publication number=WO2009117623     Event publication date=2011-10-07  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE BRPI0910268  Actual or expected expiration date=2029-03-19    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=BR Corresponding appl: BRPI0910268  Application date in the designated or member state=2009-03-19   Application number in the designated or member state=2009BR-0010268 Corresponding cc:  Designated or member state=BR Corresponding pat: BRPI0910268  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2016-04-26   Publication number in the designated or member state=BR200910268    Event publication date=2016-04-26  Event code=WO/REG  Event code=BR/B01E  Event type=Entry into national phase  Reference to a national code Information about pct entry procedure Exigencias diversas Corresponding cc:  Designated or member state=BR  REGULARIZE A PROCURACAO, UMA VEZ QUE A MESMA FOI APRESENTADA SEM DATA     Event publication date=2016-07-26  Event code=WO/ENPW  Event indicator=Neg  Event type=Event indicating Not In Force  Started to enter nat. phase and was withdrawn or failed for other reasons Corresponding cc:  Designated or member state=BR  PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2364 DE 26/04/2016.     Event publication date=2016-09-06  Event code=WO/ENPZ  Event indicator=Pos  Event type=Entry into national phase  Former announcement of the withdrawal of the entry into the national phase was wrong Corresponding cc:  Designated or member state=BR  ANULADA A PUBLICACAO 1.2 DA RPI 2377 DE 26/07/2016 EM APROVEITAMENTO DOS ATOS DAS PARTES CONFORME ALPI, UMA VEZ QUE A RESPOSTA A EXIGENCIA PUBLICADA NA RPI 2364 DE 26/04/2016 FOI RESPONDIDA COM GRU DE CODIGO ERRADO, POREM COM MESMO VALOR.     Event publication date=2016-09-13  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=BR   Effective date of the event=2010-09-20     Event publication date=2018-04-17  Event code=BR/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=BR  LEGAL DETAILS FOR DESIGNATED STATE CN102014616  Actual or expected expiration date=2015-04-15    Legal state=DEAD    Status=REVOKED   Corresponding cc:  Designated or member state=CN Corresponding appl: CN200980114921  Application date in the designated or member state=2009-03-19   Application number in the designated or member state=2009CN-80114921 Corresponding cc:  Designated or member state=CN Corresponding pat: CN102014616  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2011-04-13   Publication number in the designated or member state=CN102014616    Event publication date=2015-04-15  Event code=CN/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=CN  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2010-09-21    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2010-09-21  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE IN6682/DELNP/2010  Actual or expected expiration date=2029-03-19    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=IN Corresponding appl: IN6682/DELNP/2010  Application date in the designated or member state=2010-09-22   Application number in the designated or member state=2010IN-DN06682 Corresponding cc:  Designated or member state=IN Corresponding pat: IN6682/DELNP/2010  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2011-09-09   Publication number in the designated or member state=IN2010DN06682    Event publication date=2016-09-30  Event code=IN/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=IN  LEGAL DETAILS FOR DESIGNATED STATE MX2010010216  Actual or expected expiration date=2029-03-19    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=MX Corresponding appl: MX2010010216  Application date in the designated or member state=2009-03-19   Application number in the designated or member state=2010MX-PA10216 Corresponding cc:  Designated or member state=MX Corresponding pat: MX2010010216  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2011-02-22   Publication number in the designated or member state=MX2010010216    Event publication date=2014-08-13  Event code=MX/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=MX  LEGAL DETAILS FOR DESIGNATED STATE US2011135764  Actual or expected expiration date=2029-03-19    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=US Corresponding appl: US12936133  Application date in the designated or member state=2009-03-19   Application number in the designated or member state=2009US-12936133 Corresponding cc:  Designated or member state=US Corresponding pat: US2011135764  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2011-06-09   Publication number in the designated or member state=US20110135764    Event publication date=2011-01-28  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=US     Event publication date=2017-01-24  Event code=US/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=US  LEGAL DETAILS FOR DESIGNATED STATE ZA201006675  Actual or expected expiration date=2029-03-19    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=ZA Corresponding appl: ZA201006675  Application date in the designated or member state=2010-09-17   Application number in the designated or member state=2010ZA-0006675 Corresponding cc:  Designated or member state=ZA Corresponding pat: ZA201006675  Publication stage code in the designated or member state=B  Publication date in the designated or member state=2013-05-29   Publication number in the designated or member state=ZA201006675    Event publication date=2013-05-29  Event code=ZA/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=ZA
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部